Catalog No.
Product Name
Application
Product Information
Citations
-
Urokinase Substrate
Ac-Gly-Lys-OMe is a substrate for urokinase, primarily utilized to evaluate the enzymatic activity of this serine protease. This reagent is essential for investigating the effects of small molecule inhibitors on urokinase function in various biochemical assays and research applications focused on fibrinolysis and related pathways. -
Serine Proteases Neutrophil Elastase/Proteinase-3 Inhibitor
CE-2072 is an inhibitor of serine proteases, specifically targeting neutrophil elastase and proteinase-3. This compound demonstrates significant activity in reducing HIV-1 production and p24 levels in IL-18 or NaCl-stimulated U1 monocytic cells and peripheral blood mononuclear cells. Additionally, CE-2072 effectively inhibits HIV-1 infection in permissive HeLa cells. Its ability to suppress the transcription factor NF-kB activation in U1 cells highlights its potential in HIV-1-related disease research applications. -
TNIK Modulator
TNIK modulator-1 is a selective modulator of TNIK, a protein kinase involved in Wnt signaling pathways and neuronal development. This compound has been shown to enhance neuronal differentiation and may play a role in neurodevelopmental disorders. Its ability to regulate TNIK activity makes it a valuable tool for research in neurobiology, cancer, and regenerative medicine. -
Serine Protease Inhibitor
Laccaridione A acts as a potent serine protease inhibitor, effectively inhibiting various proteolytic enzymes including trypsin, papain, thermophilic protease, collagenase, and zinc protease, with IC50 values of 14.7 μg/mL, 2.5 μg/mL, 18.8 μg/mL, 7.2 μg/mL, and 18.2 μg/mL, respectively. This compound is valuable for studying protease activity and regulation in biological systems, making it a useful reagent in biochemical and pharmacological research applications. Its selective inhibitory properties can aid in elucidating the roles of serine proteases in various physiological and pathological processes. -
Serine Protease Inhibitor
Laccaridione B is a potent inhibitor of serine proteases, effectively inhibiting the activity of trypsin, papain, thermophilic protease, collagenase, and zinc protease with IC50 values of 10.9 μg/mL, 5.1 μg/mL, 8.4 μg/mL, 5.7 μg/mL, and 3.0 μg/mL, respectively. Additionally, Laccaridione B demonstrates significant anti-proliferative properties against various cell lines, including L-929, K-562, and HeLa cells, with IC50 values of 2.4 μg/mL, 1.8 μg/mL, and 13.9 μg/mL, respectively. These attributes make Laccaridione B a relevant compound for research in cancer biology and protease inhibition studies. -
Serine Racemase Inhibitor
L-Serine-O-sulfate potassium is an inhibitor of serine racemase (Srr), a key enzyme involved in the synthesis of D-serine, which is implicated in various neurological processes. This compound has been shown to significantly reduce chronic constriction injury (CCI)-induced increases in nitric oxide levels, nNOS phosphorylation at Ser847, and PKC-dependent GluN1 phosphorylation at Ser896. Additionally, L-Serine-O-sulfate potassium is valuable for investigating the mechanisms of peripheral neuropathy and exploring potential therapeutic interventions. -
Thrombin Inactivator
Dermatan sulphate sodium is a glycosaminoglycan that functions as a thrombin inactivator, exhibiting significant antithrombotic activity. It selectively enhances the heparin cofactor II-mediated inactivation of thrombin without affecting antithrombin III. This compound has been shown to promote stem cell differentiation and may alleviate pulmonary fibrosis induced by Bleomycin. Dermatan sulphate sodium is utilized in research focused on cardiovascular diseases, inflammation, and stem cell biology. -
Thrombin Receptor Agonist
TRAP-14 (SFLLRNPNDKYEPF) is a synthetic peptide that acts as an agonist for the thrombin receptor. This compound is utilized in research to study thrombin signaling pathways and their implications in various physiological and pathological processes. Its ability to activate the thrombin receptor makes it valuable for investigating thrombosis, inflammation, and cardiovascular diseases. -
Thrombin Inhibitor
BAY 1217224 is a selective thrombin inhibitor that acts through competitive binding to the active site of thrombin, resulting in the inhibition of fibrinogen conversion and clot formation. This compound demonstrates favorable oral pharmacokinetics, making it suitable for in vivo studies. BAY 1217224 is primarily utilized in research focused on coagulation pathways and the development of anticoagulant therapies. -
Thrombin Inhibitor
(2S,4S)-Argatroban is a potent inhibitor of human thrombin, exhibiting a Ki value of 280 μM. This compound is primarily utilized in research focused on thrombotic diseases and coagulation disorders. Its mechanism of action provides a valuable tool for studying thrombin's role in physiology and pathology, as well as for the development of therapeutic strategies targeting blood coagulation pathways. -
Thrombin Inhibitor
Corthrombin is a highly potent alpha-keto-amide thrombin inhibitor, exhibiting a Ki value of 1 pM. This compound is utilized in the study of cardiovascular diseases, providing valuable insights into thrombin-related mechanisms and potential therapeutic interventions. Its high specificity and efficacy make it an essential tool for research focused on coagulation processes and thrombotic disorders. -
Thrombin Receptor Antagonist
Thrombin receptor peptide ligand is a selective antagonist of the thrombin receptor, inhibiting its activation and downstream signaling. This compound exhibits antithrombotic properties, making it suitable for research focused on thrombotic disorders and cardiovascular diseases. Its ability to modulate thrombin activity positions it as a valuable tool for studying platelet aggregation and related pathways. -
Thrombin Inhibitor
Flovagatran is a potent and reversible thrombin inhibitor, characterized by a Ki value of 9 nM. This compound is primarily utilized in research related to arterial and venous thrombosis, providing valuable insights into thrombotic mechanisms and potential therapeutic interventions. -
Thrombin Inhibitor
Hirullin P18 is a potent thrombin inhibitor that effectively modulates coagulation pathways. This compound exhibits significant anticoagulant activity, making it valuable for research applications focused on thrombus formation and cardiovascular disorders. Hirullin P18 is an essential tool for studying thrombin-related biological processes and developing therapeutic strategies for thrombotic diseases. -
Thrombin Inhibitor
Sofigatran is an orally active thrombin inhibitor that functions as an anticoagulant by selectively targeting factor IIa. This compound exhibits significant biological activity in modulating blood coagulation pathways and is particularly relevant in cardiovascular disease research. Its utility in preclinical studies facilitates the exploration of its therapeutic potential in managing thrombotic disorders. -
Neutral Thrombin Inhibitor
AZD-8165 is a highly selective neutral thrombin inhibitor that demonstrates potent anticoagulant properties. This compound is primarily utilized in research related to cardiovascular diseases, including hypertension and heart failure. Its mechanism of action aids in elucidating thrombotic processes and evaluating therapeutic strategies in related cardiovascular conditions. -
α-Thrombin Substrate
Sar-Pro-Arg-pNA serves as a chromogenic substrate specifically for α-thrombin. It enables the assessment of α-thrombin activity through colorimetric measurements, making it a valuable tool in coagulation studies and thrombin activity assays. This substrate is suitable for research applications that investigate thrombin's role in hemostasis and related disorders. -
Thrombin Inhibitor
L 373890 is a selective thrombin inhibitor characterized by its low Ki value of 0.5 nM, indicating potent activity against thrombin. This compound exhibits high selectivity, showing a significantly reduced Ki of 570 nM for trypsin and minimal inhibition of other serine proteases, such as plasmin and tPA. L 373890 is a valuable tool for researchers investigating thrombosis and related cardiovascular disorders. -
Thrombin Inhibitor
Efegatran is a potent thrombin inhibitor that effectively prevents platelet aggregation. Its anticoagulant and antithrombotic properties make it valuable for research applications focused on cardiovascular health and clotting disorders. This compound serves as an important tool for studying thrombin-related mechanisms and evaluating potential therapeutic strategies in the management of thromboembolic diseases. -
Thrombin Inhibitor
Atecegatran TFA is a selective direct thrombin inhibitor that acts as a potent anticoagulant. It plays a significant role in the management of cardiovascular diseases by effectively inhibiting thrombin, thereby preventing thrombus formation. The active form of this compound, AR-H067637, is critical for its anticoagulation effects and is utilized in various research applications focused on thrombotic disorders and cardiovascular health. -
Thrombin Inhibitor
CVS-1123 is an orally active direct thrombin inhibitor targeting thrombin activity. This compound effectively inhibits in vitro platelet aggregation induced by γ-thrombin and prolongs activated partial thromboplastin time. CVS-1123 modulates the thrombotic response to deep vessel wall injury in both arterial and venous systems, making it a valuable tool for antithrombotic research. -
Thrombin Cleavable Peptide
Thrombin-cleavable peptide targets thrombin and is specifically designed for thrombin recognition and cleavage. Upon enzymatic cleavage, it releases thrombolytic peptides that play a crucial role in initiating thrombolysis. This reagent is valuable for research applications related to ischemic stroke and other thrombotic conditions. -
Thrombin Inhibitor
(2R)-Atecegatran is a selective thrombin inhibitor that demonstrates significant anticoagulant activity. This compound is employed in research concerning thromboembolic disorders, aiding in the understanding of coagulation pathways and potential therapeutic strategies. Its effectiveness in modulating thrombin activity makes it a valuable tool in the development of anticoagulant therapies. -
Thrombin Inhibitor
S-18326 is an orally active direct thrombin inhibitor that functions by reversibly binding to the active site of thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting thrombus formation. This compound effectively prolongs clotting times in human plasma and has shown antithrombotic efficacy in various animal models while maintaining normal platelet levels. S-18326 is suitable for research applications related to thromboembolic diseases. -
Thrombin/Factor Xa Inhibitor
SAR107375 is a potent dual inhibitor of thrombin and factor Xa, exhibiting Ki values of 1 nM for factor Xa and 8 nM for thrombin. This compound demonstrates significant anticoagulant activity, making it a valuable tool for research applications focused on thrombosis and coagulation disorders. SAR107375 can be utilized in the study of cardiovascular diseases and the development of novel anticoagulant therapies. -
Thrombin Inhibitor
Thrombin Inhibitor 6 is a highly potent anticoagulant that functions by specifically inhibiting thrombin with an IC50 of 1 nM. This compound is valuable for research applications in anticoagulant therapy and thrombotic disease studies, enabling the exploration of thrombin's role in hemostasis and thrombosis. -
Thrombin Inhibitor
SSR182289 is a selective and potent inhibitor of thrombin, demonstrating competitive inhibition with a Ki of 0.031 µM. This compound exhibits significant anticoagulant activity, achieving an EC100 of 96 nM in thrombin time assays, and effectively inhibits tissue factor-induced thrombin generation with an IC50 of 0.15 µM in human plasma. Additionally, SSR182289 inhibits thrombin-induced aggregation of human platelets with an IC50 of 32 nM, while showing no effect on aggregation induced by other agonists. Such properties make SSR182289 valuable for research into anticoagulation and thrombotic disorders. -
Thrombin Inhibitor
Napsagatran is a potent inhibitor of thrombin, a key enzyme in the coagulation cascade. It demonstrates significant anticoagulant effects both in vitro and in vivo, making it a valuable tool for studying thrombus formation and related cardiovascular functions. This compound is suitable for antithrombotic research applications, contributing to the understanding of thrombotic disorders and potential therapeutic interventions. -
Thrombin Inhibitor
Efegatran sulfate is a potent thrombin inhibitor that effectively inhibits platelet aggregation, demonstrating significant anticoagulant and antithrombotic properties. This compound is valuable for research focused on cardiovascular diseases, hemostasis, and thrombosis. Its mechanism of action makes it a crucial tool for studying thrombin-related pathways and potential therapeutic interventions in coagulation disorders. -
Thrombin Inhibitor
(1R,3S)-THCCA-Asn is a selective thrombin inhibitor that effectively demonstrates anticoagulant properties with an IC50 value between 0.07 to 0.14 μM. This compound is valuable in research applications focused on thrombosis, hemostasis, and the development of therapeutic agents targeting thrombin. Its specific inhibition of thrombin makes it a significant tool for investigating antithrombotic mechanisms and potential cardiovascular therapies. -
Thrombin Inhibitor
BMS 180742 is a selective thrombin exosite inhibitor that disrupts thrombin's ability to interact with its substrates. It exhibits significant inhibition of thrombin-mediated processes, making it a valuable tool for investigating coagulation pathways. This compound is particularly useful in research applications focusing on the modulation of hemostasis and thrombin-related disorders. Notably, BMS 180742 does not exhibit inhibition of arterial thrombosis, providing insights into selective targeting in thrombosis research. -
Thrombin Inhibitor
AT-1459 is a selective, orally active direct thrombin inhibitor with a Ki value of 4.9 nM. It demonstrates significant antithrombotic activity in both rat models of venous and arterial thrombosis, making it a valuable tool for studying thrombosis-related diseases. AT-1459 is suitable for research applications focused on blood coagulation and associated pathologies. -
Thrombin Inhibitor
BCH-2763 is a potent and selective thrombin inhibitor, exhibiting a high affinity for thrombin with a Ki value of 0.11 nM. This compound effectively inhibits fibrin formation, platelet aggregation, and the activity of free thrombin. BCH-2763 is suitable for research applications focused on thrombosis and related cardiovascular studies. -
Thrombin Inhibitor
Efegatran dihydrochloride is a potent thrombin inhibitor that effectively prevents platelet aggregation. This compound exhibits significant anticoagulant and antithrombotic properties, making it valuable for studies related to cardiovascular diseases and clotting disorders. Its mechanism of action provides insight into thrombin-related pathways in various biological research applications. -
Thrombin Inhibitor
LY135305 is a selective thrombin inhibitor that impedes thrombin activation. This compound demonstrates significant anti-metastatic properties, reducing spontaneous metastasis and contributing to improved survival rates in animal models. It is utilized in research focused on thrombin-related pathways and cancer metastasis. -
Thrombin Inhibitor
(21S)-Argatroban is a specific thrombin inhibitor known for its anticoagulant properties. By interfering with thrombin activity, it effectively prolongs blood clotting time, while also reducing platelet adhesion and aggregation. This compound is useful in research applications aimed at understanding coagulation disorders and developing therapeutic strategies for thrombotic diseases. -
Thrombin Inhibitor
Ro 09-1679 is a potent thrombin inhibitor with an IC50 of 33.6 μM, demonstrating significant inhibition of thrombin activity. Additionally, it effectively inhibits factor Xa, trypsin, and papain, with IC50 values of 3.3 μM, 0.04 μM, and 0.0346 μM, respectively. This compound is valuable for research applications focused on coagulation pathways, providing insights into thrombin's role in hemostasis and potential therapeutic interventions. -
Thrombin Inhibitor
NAPAP is a selective direct thrombin inhibitor that binds rapidly to thrombin, effectively inhibiting its enzymatic activity. This compound demonstrates significant potential in reducing lipopolysaccharide (LPS)-induced neuroinflammation and expression of coagulation factors in vivo. NAPAP is valuable for research applications focused on coagulation pathways and neuroinflammatory processes. -
Thrombin Inhibitor
LK-732 is a selective thrombin inhibitor that demonstrates significant anti-thrombotic activity. It exhibits dose-dependent inhibition of hypercoagulability, with an IC50 of 1.3 mg/kg. This compound is suitable for use in cardiovascular and cerebrovascular research applications, providing insights into thrombotic disorders and potential therapeutic interventions. -
Thrombin Inhibitor
DuP 714 is a potent oral thrombin inhibitor that effectively inhibits thrombin-induced platelet aggregation with an IC50 value of 150 nM. This compound is valuable for research into arterial thrombosis, allowing for the investigation of thrombin's role in platelet activation and clot formation. Its selective mechanism makes it a crucial tool for studies aimed at understanding cardiovascular diseases and developing therapeutic strategies. -
Thrombin Inhibitor
LY 806303 is a selective inhibitor of human α-thrombin, functioning primarily through the acylation of Ser-205 within the enzyme's catalytic triad. This modification disrupts the enzymatic activity of thrombin, delineating its role in various coagulation processes. LY 806303 is valuable for research applications focused on thrombin's involvement in hemostasis and thrombosis, providing insights into therapeutic strategies for related diseases. -
α-thrombin Inhibitor
RWJ-671818 is a potent oral inhibitor of human α-thrombin, exhibiting a Ki of 1.3 nM. This compound is particularly relevant in the study of venous and arterial thrombosis, providing insights into thrombotic mechanisms and potential therapeutic interventions. Its specificity for α-thrombin makes it a valuable tool in anticoagulant research. -
a-thrombin Inhibitor
BMS-189664 hydrochloride is a potent and selective reversible inhibitor of alpha-thrombin, exhibiting an IC50 value of 0.046 μM. This compound demonstrates significant anti-thrombotic activity and is suitable for research applications related to arterial and venous thrombosis. Its oral bioavailability makes it a valuable tool for in vivo studies of thrombotic disorders. -
a-thrombin Inhibitor
BMS-189664 is a selective and reversible inhibitor of α-thrombin, exhibiting a potent IC50 of 0.046 μM. This compound is valuable for investigating mechanisms involved in arterial and venous thrombosis. Its orally active nature facilitates its use in preclinical studies aimed at understanding thrombotic disorders and potential therapeutic interventions. -
Thrombin Inhibitor
Napsagatran hydrate is a potent thrombin inhibitor that effectively antagonizes thrombin activity. It demonstrates significant anticoagulant effects both in vitro and in vivo, making it a valuable reagent for antithrombotic research. This compound is suitable for studies focused on coagulation and related pathways, contributing to the development of therapeutics for thrombotic disorders. -
Thrombin Inhibitor
Atecegatran is an orally active competitive thrombin inhibitor targeting thrombin with a Ki value of 2-4 nM. By blocking thrombin's interaction with fibrin and thrombomodulin, it effectively inhibits platelet activation and aggregation. Demonstrating significant anticoagulant properties, Atecegatran exhibits an IC50 range of 93 to 220 nM in various plasma coagulation assays. This reagent is valuable for research focused on thromboembolic disorders and related cardiovascular studies. -
Thrombin Inhibitor
Flovagatran sodium is a potent and reversible thrombin inhibitor with a Ki of 9 nM. This compound demonstrates significant efficacy in studies related to arterial and venous thrombosis, making it a valuable tool for hematological research. Its ability to selectively target thrombin enhances its utility in elucidating mechanisms of coagulation and developing therapeutic strategies for thrombotic disorders. -
Thrombin synthetase Inhibitor
Pirmagrel is a thrombin synthetase inhibitor that effectively reduces thrombin secretion stimulated by lipopolysaccharide. Its primary mechanism involves the inhibition of thrombin synthesis, making it a valuable tool for studies related to coagulation and inflammation. This reagent is applicable in research focusing on thrombotic disorders and assessing the biological pathways influenced by thrombin regulation. -
Thrombin Inhibitor
LB30057 (CI-1028) is a selective thrombin inhibitor with an inhibitory concentration (IC50) of 0.38 nM for human thrombin. This orally active compound is suitable for research on thrombus formation and related cardiovascular studies, making it a valuable tool for investigations into coagulation disorders and antithrombotic therapies. -
Thrombin Inhibitor
Thrombin inhibitor 1 is a potent thrombin inhibitor with a Ki value of 0.66 nM and a 2xaPTT of 0.43 μM. This compound effectively inhibits thrombin activity, making it a valuable tool for studying blood coagulation and developing anticoagulant therapies. Its high specificity and efficacy render it suitable for various research applications in cardiovascular and hemostasis studies.
